Victory Capital Management Inc. Has $1.66 Million Holdings in Catalent, Inc. (NYSE:CTLT)

Victory Capital Management Inc. decreased its stake in shares of Catalent, Inc. (NYSE:CTLT) by 4.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 27,360 shares of the company’s stock after selling 1,172 shares during the period. Victory Capital Management Inc.’s holdings in Catalent were worth $1,657,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Sumitomo Mitsui Trust Group Inc. increased its stake in Catalent by 3.7% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 405,318 shares of the company’s stock valued at $24,550,000 after buying an additional 14,373 shares during the last quarter. Swedbank AB bought a new stake in Catalent during the first quarter worth about $1,659,000. New York Life Investment Management LLC boosted its position in Catalent by 67.9% during the second quarter. New York Life Investment Management LLC now owns 297,903 shares of the company’s stock valued at $16,751,000 after purchasing an additional 120,502 shares during the last quarter. Van ECK Associates Corp boosted its position in Catalent by 47.4% during the third quarter. Van ECK Associates Corp now owns 124,424 shares of the company’s stock valued at $7,391,000 after purchasing an additional 39,983 shares during the last quarter. Finally, Squarepoint Ops LLC increased its position in shares of Catalent by 346.9% during the 2nd quarter. Squarepoint Ops LLC now owns 205,689 shares of the company’s stock worth $11,566,000 after purchasing an additional 159,665 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the company. Baird R W downgraded Catalent from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. Robert W. Baird reiterated a “neutral” rating and issued a $63.50 price target on shares of Catalent in a research note on Tuesday, September 24th. William Blair restated a “market perform” rating on shares of Catalent in a research note on Tuesday, September 3rd. Finally, StockNews.com downgraded shares of Catalent from a “hold” rating to a “sell” rating in a research note on Friday. One research analyst has rated the stock with a sell rating and seven have given a hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $63.40.

Catalent Price Performance

Shares of CTLT opened at $61.24 on Tuesday. The company’s 50-day moving average is $59.81 and its 200-day moving average is $58.32. The company has a debt-to-equity ratio of 1.38, a current ratio of 2.51 and a quick ratio of 1.96. The firm has a market capitalization of $11.12 billion, a PE ratio of -26.99, a PEG ratio of 2.42 and a beta of 1.16. Catalent, Inc. has a fifty-two week low of $36.74 and a fifty-two week high of $61.50.

Catalent (NYSE:CTLT) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.18). Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. The company had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.06 billion. During the same period in the prior year, the company earned ($0.10) earnings per share. The firm’s revenue was up 4.2% compared to the same quarter last year. Equities analysts forecast that Catalent, Inc. will post 0.84 EPS for the current year.

Insider Buying and Selling

In other Catalent news, Director Michelle R. Ryan sold 2,800 shares of the firm’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $59.70, for a total value of $167,160.00. Following the transaction, the director now directly owns 10,835 shares of the company’s stock, valued at $646,849.50. This trade represents a 20.54 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider David Mcerlane sold 1,994 shares of the firm’s stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $59.97, for a total value of $119,580.18. Following the completion of the sale, the insider now directly owns 36,304 shares in the company, valued at approximately $2,177,150.88. This represents a 5.21 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 5,114 shares of company stock valued at $305,931. Insiders own 0.31% of the company’s stock.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.